Literature DB >> 23322007

Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon.

Sonali Kochhar1.   

Abstract

Vaccines have had a major role in enhancing the quality of life and increasing life expectancy. Despite these successes and the development of new vaccine technologies, there remain multiple infectious diseases including AIDS, malaria and tuberculosis that require effective prophylactic vaccines. New and traditional technologies have a role in the development and delivery of the new vaccine candidates. The scientific challenges, opportunities and funding models for developing vaccines for low resource settings are highlighted here.

Entities:  

Keywords:  challenges; countries; developing; emerging; opportunities; vaccines

Mesh:

Substances:

Year:  2013        PMID: 23322007      PMCID: PMC3903916          DOI: 10.4161/hv.23514

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  14 in total

Review 1.  Transdermal immunization: biological framework and translational perspectives.

Authors:  Dinesh Kumar Mishra; Vinod Dhote; Pradyumna Kumar Mishra
Journal:  Expert Opin Drug Deliv       Date:  2012-12-21       Impact factor: 6.648

2.  Innovative financing for health: what is truly innovative?

Authors:  Rifat Atun; Felicia Marie Knaul; Yoko Akachi; Julio Frenk
Journal:  Lancet       Date:  2012-10-24       Impact factor: 79.321

Review 3.  Killed but metabolically active vaccines.

Authors:  Thomas W Dubensky; Justin Skoble; Peter Lauer; Dirk G Brockstedt
Journal:  Curr Opin Biotechnol       Date:  2012-05-18       Impact factor: 9.740

4.  Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.

Authors:  Mariana Baz; Mukesh Samant; Hakima Zekki; Pascale Tribout-Jover; Martin Plante; Anne-Marie Lanteigne; Marie-Eve Hamelin; Corey Mallett; Barbara Papadopoulou; Guy Boivin
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

5.  A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.

Authors:  Paul Spearman; Michelle A Lally; Marnie Elizaga; David Montefiori; Georgia D Tomaras; M Juliana McElrath; John Hural; Stephen C De Rosa; Alicia Sato; Yunda Huang; Sharon E Frey; Paul Sato; John Donnelly; Susan Barnett; Lawrence J Corey
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

6.  Product Development Partnerships: Case studies of a new mechanism for health technology innovation.

Authors:  Richard T Mahoney
Journal:  Health Res Policy Syst       Date:  2011-08-26

7.  Controlling dengue with vaccines in Thailand.

Authors:  Dennis L Chao; Scott B Halstead; M Elizabeth Halloran; Ira M Longini
Journal:  PLoS Negl Trop Dis       Date:  2012-10-25

Review 8.  Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.

Authors:  Natasha Kushnir; Stephen J Streatfield; Vidadi Yusibov
Journal:  Vaccine       Date:  2012-11-06       Impact factor: 3.641

Review 9.  Vaccines for the twenty-first century society.

Authors:  Rino Rappuoli; Christian W Mandl; Steven Black; Ennio De Gregorio
Journal:  Nat Rev Immunol       Date:  2011-11-04       Impact factor: 53.106

10.  Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination.

Authors:  Laurent Coudeville; Geoff P Garnett
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.